Back to Barclays plc Barclays plc

JANX

Showing 9 of 19 quarters

Position history for Barclays plcBarclays plc's holdings in Janux Therapeutics, Inc.

Yes. Barclays holds 68,611 shares of JANX (Janux Therapeutics), worth $1.2M, as of its Q3 2026 13F filing. It increased the position by 4,932 shares (+7.8%) from Q2 2026. Barclays has held JANX since Q1 2022, across 19 quarterly 13F filings.

Current Value

$1.2M

Current Shares

68,611

Total Value Change

-$6.7M

Total Shares Change

-105,450

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q3
Latest
Increased
68,611
+7.8%
$1.2M0.0%$17.28
27
2026-Q2
Increased
63,679
+13.7%
$978,1100.0%$15.36
28
2026-Q1
Decreased
55,988
-74.7%
$778,2320.0%$13.90
0
2025-Q4
Increased
221,233
+53.6%
$3.1M0.0%$13.80
37
2025-Q3
Increased
144,024
+8.8%
$3.5M0.0%$24.44
29
2025-Q2
Increased
132,341
+95.3%
$3.1M0.0%$23.10
42
2025-Q1
Decreased
67,766
-74.3%
$1.8M0.0%$27.00
0
2024-Q4
Increased
263,970
+51.6%
$14.1M0.0%$53.54
39
2024-Q3
Increased
174,061
+496.6%
$7.9M0.0%$46.25
44

Other major holders of JANX: RA Capital Management, L.P., FMR LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used